The latest price target for Candel Therapeutics (NASDAQ:CADL) was reported by HC Wainwright & Co. on November 18, 2024. The analyst firm set a price target for $11.00 expecting CADL to rise to within 12 months (a possible 114.84% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Candel Therapeutics (NASDAQ:CADL) was provided by HC Wainwright & Co., and Candel Therapeutics reiterated their buy rating.

There is no last upgrade for Candel Therapeutics

There is no last downgrade for Candel Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Candel Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Candel Therapeutics was filed on November 18, 2024 so you should expect the next rating to be made available sometime around November 18, 2025.

While ratings are subjective and will change, the latest Candel Therapeutics (CADL) rating was a reiterated with a price target of $11.00 to $11.00. The current price Candel Therapeutics (CADL) is trading at is $5.12, which is out of the analyst’s predicted range.